Lin TC, et al. - Experts evaluated hepatitis B virus (HBV) reactivation rates in patients with resolved or chronic HBV infection, receiving disease-modifying antirheumatic drugs (DMARDs) and with or without antiviral prophylaxis. They noted low HBV reactivation rate in inflammatory arthritis patients receiving DMARDs, in resolved patients and in patients with chronic HBV infection it was seen to be moderate. Moreover, in patients with chronic HBV infection who were using antiviral prophylaxis lower rates were noted.